These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 19664627

  • 1. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 2. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ.
    Aliment Pharmacol Ther; 2008 Nov 01; 28(9):1122-6. PubMed ID: 18691349
    [Abstract] [Full Text] [Related]

  • 4. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May 01; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.
    Gut; 2007 Sep 01; 56(9):1232-9. PubMed ID: 17299059
    [Abstract] [Full Text] [Related]

  • 6. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.
    Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):273-8. PubMed ID: 19006540
    [Abstract] [Full Text] [Related]

  • 7. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 01; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

  • 8. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.
    Eur J Gastroenterol Hepatol; 2010 Mar 01; 22(3):334-9. PubMed ID: 19528808
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F, Giudici F, Asteria CR.
    Dis Colon Rectum; 2012 Aug 01; 55(8):870-5. PubMed ID: 22810472
    [Abstract] [Full Text] [Related]

  • 10. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P.
    Gut; 2012 Feb 01; 61(2):229-34. PubMed ID: 21948942
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L, Laclotte C, Bigard MA.
    Aliment Pharmacol Ther; 2007 Mar 15; 25(6):675-80. PubMed ID: 17311600
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 15; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 13. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T.
    J Gastrointestin Liver Dis; 2012 Sep 15; 21(3):265-9. PubMed ID: 23012667
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
    Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Feb 15; 29(4):416-23. PubMed ID: 19035976
    [Abstract] [Full Text] [Related]

  • 15. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
    Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ.
    Arch Dermatol; 2010 Feb 15; 146(2):127-32. PubMed ID: 20157022
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A, Martinsen TC, Waldum HL, Fossmark R.
    Scand J Gastroenterol; 2012 Jun 15; 47(6):649-57. PubMed ID: 22472026
    [Abstract] [Full Text] [Related]

  • 17. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.
    Gastroenterology; 2008 Nov 15; 135(5):1493-9. PubMed ID: 18848553
    [Abstract] [Full Text] [Related]

  • 18. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB, Sagynbaeva VÉ.
    Eksp Klin Gastroenterol; 2013 Nov 15; (7):18-22. PubMed ID: 24772870
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E.
    Scand J Gastroenterol; 2016 Sep 01; 51(9):1081-6. PubMed ID: 27207330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.